Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo + docetaxel (Hengrui Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
placebo + docetaxel refers to the control treatment arm used in clinical research conducted by Jiangsu HengRui Medicine Co., Ltd., specifically within the Phase III trial (NCT02766140) for patients with advanced non-squamous non-small cell lung cancer (NSCLC). This combination consists of docetaxel, a microtubule-stabilizing antineoplastic agent administered intravenously, and an oral placebo that matches the experimental drug famitinib (SHR1020). Docetaxel works by binding to tubulin, promoting its assembly into microtubules and inhibiting their disassembly, which leads to cell cycle arrest in the G2/M phase and subsequent apoptosis. The placebo component ensures the double-blind nature of the study, serving as a pharmacologically inactive comparator to isolate the therapeutic effects of famitinib when added to the standard docetaxel regimen.
- Other names
- Placebo plus Docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on placebo + docetaxel (Hengrui Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo + docetaxel (Hengrui Pharmaceutical).